|
Apr 8
|
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
|
|
Apr 7
|
ImmuCell Hires Chief Financial Officer
|
|
Apr 3
|
ImmuCell Full Year 2024 Earnings: US$0.26 loss per share (vs US$0.74 loss in FY 2023)
|
|
Apr 2
|
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
|
|
Feb 20
|
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
|
|
Feb 18
|
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell
|
|
Aug 16
|
ImmuCell Second Quarter 2024 Earnings: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023)
|
|
Aug 13
|
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
|
|
May 8
|
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
|
|
Apr 9
|
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
|
|
Aug 7
|
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
|